COVID-19 convalescent plasma (Direction Centrale du Service de Santé des Armées)

COVID-19 convalescent plasma is a passive immunotherapy consisting of plasma collected from donors who have recovered from COVID-19, containing high titers of neutralizing antibodies against SARS-CoV-2. Developed by the Direction Centrale du Service de Santé des Armées for the PlasCoSSA clinical trial, this specific preparation involves amotosalen-inactivated plasma units. The mechanism of action involves the binding of donor antibodies to the SARS-CoV-2 spike protein, preventing viral entry into host cells and reducing viral load. It is primarily investigated for the treatment of hospitalized COVID-19 patients to prevent respiratory failure and disease progression.

Other names

SARS-CoV-2 convalescent plasmaSARS-CoV2 convalescent plasmaSARS-CoV 2 convalescent plasmaConvalescent plasmaCCP